Groundbreaking Treatment Offers Hope for Patients with Advanced Multiple Myeloma
A powerful combination therapy has emerged as a beacon of hope for patients battling a severe form of multiple myeloma, but the results have sparked both excitement and debate among experts.
The RedirecTT-1 study, presented at the 2025 American Society of Hematology (ASH) Annual Meeting, reveals that the combination of talquetamab and teclistamab delivers remarkable results for patients with a challenging form of relapsed/refractory multiple myeloma (MM) and extramedullary disease (EMD).
Study Details and Patient Population:
The Phase 2 trial involved 90 patients with triple-class exposed relapsed/refractory MM and true EMD. These patients received subcutaneous talquetamab (0.8 mg/kg) and teclistamab (3.0 mg/kg) every 2 weeks, with a median follow-up period of 16.2 months.
The patient group was characterized by a high disease burden, with 82.2% having soft tissue involvement, 32.2% with organ EMD (mainly liver), and 18.9% with nodal involvement. Notably, 39% had non-secretory/oligo-secretory disease, and 20% had prior BCMA CAR-T exposure.
Impressive Efficacy and Safety Profile:
The study's results are compelling: the overall response rate (ORR) was 77.8%, with half of the patients achieving a complete response (CR) or better. The 12-month duration of response (DOR) was 60.1%, progression-free survival (PFS) was 55.6%, and overall survival (OS) was 73.8%.
But here's where it gets interesting: response rates were significantly higher in patients with smaller EMD tumor volumes. Patients with EMD tumor volume <25 cm² had an ORR of 90.7% and CR ≥60.5%. However, as tumor volume increased, response rates declined.
Regarding safety, the combination therapy was well-tolerated. No grade 3 or higher cytokine release syndrome (CRS) was reported, and immune effector cell-associated neurotoxicity syndrome occurred in 12.2% of patients, with only 2.2% being grade 3 or higher. Common adverse events included taste changes (79%), skin events (69%), and nail changes (56%). Grade 3/4 neutropenia and infections were observed in 62.2% and 40% of patients, respectively.
Expert Insights and Implications:
The study's researchers assert that the combination of Tal and Tec demonstrates superior efficacy compared to all approved therapies for this patient population, including T-cell redirecting and cellular therapies. This claim is significant, but it also raises questions about the direct comparison of therapies across different studies.
The unique combination of Tal and Tec offers a promising treatment option for patients with true EMD, a group with limited treatment options and a significant unmet need.
And this is the part most people miss: the study's findings could potentially influence treatment strategies for patients with advanced MM and EMD, offering a new ray of hope. However, the optimal timing and sequencing of this combination therapy within the broader treatment landscape remain subjects of ongoing research and debate.
What are your thoughts on these groundbreaking results? Do you think this combination therapy could become a game-changer for patients with EMD-associated MM? Share your insights and join the discussion!
